Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 79% Improvement Relative Risk Improvement 85% c19early.org/o Pimenta Bonifácio et al. NCT04724629 Colchicine RCT LATE Is late treatment with colchicine beneficial for COVID-19? RCT 30 patients in Brazil Lower mortality (p=0.49) and greater improvement (p=0.23), not stat. sig. Pimenta Bonifácio et al., SSRN Electronic J., doi:10.2139/ssrn.4095747 Favors colchicine Favors control
Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care on the treatment of patients hospitalized with moderate to critical Covid-19: a pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors)
Pimenta Bonifácio et al., SSRN Electronic Journal, doi:10.2139/ssrn.4095747, NCT04724629 (history)
Pimenta Bonifácio et al., Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care on the treatment of.., SSRN Electronic Journal, doi:10.2139/ssrn.4095747, NCT04724629
Apr 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Open label RCT late stage hospitalized patients in Brazil with 14 colchicine and 16 SOC patients, showing lower mortality and improved recovery with treatment, without statistical significance. Authors note that the colchicine group had one patient with SOFA ≥7 vs. zero for SOC, however both groups had one patient intubated and SOC had more patients not requiring high-flow oxygen (12 vs. 8).
risk of death, 78.9% lower, RR 0.21, p = 0.49, treatment 0 of 14 (0.0%), control 2 of 16 (12.5%), NNT 8.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of no improvement, 84.9% lower, RR 0.15, p = 0.23, treatment 0 of 14 (0.0%), control 3 of 16 (18.8%), NNT 5.3, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Pimenta Bonifácio et al., 28 Apr 2022, Randomized Controlled Trial, Brazil, peer-reviewed, 20 authors, dosage 1.5mg days 1-3, 1mg days 4-28, trial NCT04724629 (history).
Contact: fbellissimo@usp.br, livia_pb@usp.br.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperColchicineAll
Abstract: pe er re vie we d Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care on the treatment of patients hospitalized with moderate to critical Covid-19: a pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors) Running title: Exploring new targets for Covid-19 treatment Lívia Pimenta Bonifácio, Ph.D.,1* Eduardo Ramacciotti, Ph.D.,2,3* Leandro Barile Agati*, Ph.D.,2,3 Fernando Crivelenti Vilar, Ph.D,1 Anna Christina Tojal da Silva, MD.,1 Paulo Louzada Júnior, Ph.D.,1 Benedito Antônio Lopes da Fonseca, Ph.D.,1 Hayala Cristina Cavenague de Souza, Ph.D.,1 Caroline Candida Carvalho de Oliveira, MD.,2,3 Valéria Cristina Resende Aguiar, MD., 2,3 Carlos Augusto de Aguiar Quadros, MD., 3 Cesar Dusilek, MD.,4 Kenji Itinose, MD.,4 Ricardo Gustavo Zill Risson, MD.,4 Lucas Roberto Rivabem Ferreira, MD.,4 Rogério Aparecido Dedivitis, Ph.D.,5 André Sementilli Cortina, MD.,5 Renato Delascio Lopes, Ph.D.,6,7 Esper Georges Kallas, Ph.D.,8 and Fernando Bellissimo-Rodrigues, Ph.D.1 *contributed equally to the present study 1Ribeirão Preto Medical School, University of São Paulo - FMRP / USP. Ribeirão Preto. São ot Paulo. Brazil 2Science Valley Research Institute, São Paulo, SP, Brazil 3Hospital e Maternidade Christóvão da Gama, Grupo Leforte, Santo André, SP, Brazil 4Hospital do Rocio, Campo Largo, Paraná, Brazil 5Irmandade da Santa Casa da Misericórdia de Santos, São Paulo, Brazil 6 Brazilian Clinical Research Institute, São Paulo, SP, Brazil 7Duke University Medical Center – Duke Clinical Research Institute, Durham, North Carolina. 8 Department of Infectious and Parasitic Diseases, School of Medicine, University of São Paulo, SP, Brazil tn Corresponding Author: Fernando Bellissimo-Rodrigues Social Medicine Department, Ribeirão Preto Medical School (USP) Campus Universitário, Monte Alegre 14048-900, Ribeirão Preto, São Paulo, Brazil Phone: (+5516) 3602-2536 Email: fbellissimo@usp.br Pr ep rin Lívia Pimenta Bonifácio Social Medicine Department, Ribeirão Preto Medical School (USP) Campus Universitário, Monte Alegre 14048-900, Ribeirão Preto, São Paulo, Brazil Phone: (+5516) 3602-2536 Email: livia_pb@usp.br This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=4095747 d ABSTRACT Pr ep rin tn ot pe er re vie we Background: To evaluate the efficacy and safety of Ixekizumab (IL-17 inhibitor), or low-dose IL-2 or colchicine on top of standard of care (SOC) for Covid-19 treatment. Methods: A multicenter, open-label, randomized, adaptive study of 4 treatment arms conducted in Brazil. Hospitalized patients with moderate to critical Covid-19 were enrolled according to predetermined eligibility criteria. Patients were randomized to one of 4 arms: standard of care (SOC) alone or combined with Ixekizumab, or low-dose IL-2 or colchicine. The primary efficacy outcome was accessed in the “per protocol” population as the proportion of patients with clinical improvement, defined as a two-point decrease on the WHO sevencategory ordinal scale at day 28 after randomization. Findings: 60 patients were enrolled in the study: 16 in the SOC group, 16 in the Ixekizumab group, 14 in the low-dose IL-2 group, and 14 in the colchicine group. Patients assigned to the colchicine arm presented the greatest improvement in the WHO scale (100%) by day 28, while those in the low dose IL-2 had the worse improvement (64.3%). The colchicine arm presented the..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit